KBY Biotech Indexv0.0.34
Search
← Pipeline|BLP-8787

BLP-8787

Approved
By Bellerophon
Source: Trial-derived·Trials: 4
Modality
Bispecific Ab
MOA
CD47i
Target
TIM-3
Pathway
Ferroptosis
Huntington'sAML
Development Pipeline
Preclinical
~May 2011
→ ~Aug 2012
Phase 1
~Nov 2012
→ ~Feb 2014
Phase 2
~May 2014
→ ~Aug 2015
Phase 3
~Nov 2015
→ ~Feb 2017
NDA/BLA
~May 2017
→ ~Aug 2018
Approved
Nov 2018
→ Aug 2028
ApprovedCurrent
NCT08270395
2,342 pts·Huntington's
2021-01→2025-06·Active
NCT06998485
2,634 pts·Huntington's
2023-07→2028-08·Recruiting
NCT06203374
2,423 pts·Huntington's
2018-11→2027-02·Recruiting
+1 more trial
10,086 total pts2 indications
CompletedCurrentUpcoming
Catalysts (4)
2025-06-0210mo agoPh3 Readout· Huntington's
2025-06-0810mo agoPh3 Readout· AML
2027-02-1511mo awayPh3 Readout· Huntington's
2028-08-092.4y awayPh3 Readout· Huntington's
Trial Timeline
Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
Approved
Recruit…
Approved
Termina…
Approved
Active
Approved
Recruit…
Catalysts
Ph3 Readout
2025-06-02 · 10mo ago
Huntington's
Ph3 Readout
2025-06-08 · 10mo ago
AML
Ph3 Readout
2027-02-15 · 11mo away
Huntington's
Ph3 Readout
2028-08-09 · 2.4y away
Huntington's
RecruitingActiveTerminated|StartCompletionToday
Trials (4)
NCTPhaseIndicationStatusNEP
NCT08270395ApprovedHuntington'sActive2342PASI75
NCT06998485ApprovedHuntington'sRecruiting26346MWD
NCT06203374ApprovedHuntington'sRecruiting2423PANSS
NCT06146108ApprovedAMLTerminated2687CfB
Competitors (10)
DrugCompanyPhaseTargetMOA
NirarelsinJohnson & JohnsonPhase 2PRMT5CD47i
CevizanubrutinibJohnson & JohnsonPreclinicalFcRnCD47i
CeviglumideRocheNDA/BLAB7-H3CD47i
NVS-1475NovartisPhase 2MeninCD47i
AZN-6294AstraZenecaPhase 2/3APOC3CD47i
ZenonesiranGSKPreclinicalDLL3CD47i
AMG-7379AmgenPreclinicalDLL3CD47i
REG-6699RegeneronPhase 2/3TIM-3FcRni
BGN-3859BeiGeneApprovedPSMACD47i
ZanurapivirNeurocrineNDA/BLAEGFRCD47i